Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

August 26, 2021

Study Completion Date

August 26, 2021

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

Lanadelumab

Lanadelumab solution, SC

Trial Locations (12)

441-8570

Toyohashi Municipal Hospital, Toyohashi

289-2511

Asahi General Hospital, Asahi-shi

503-8502

Ogaki Municipal Hospital, Ogaki-shi

734-8551

Hiroshima University Hospital, Hiroshima

053-8567

Tomakomai City Hospital, Tomakomai-shi

650-0017

Kobe University Hospital, Kobe

259-1193

Tokai University Hospital, Isehara-shi

236-0004

Yokohama City University Hospital, Yokohama

606-8507

Kyoto University Hospital, Kyoto

565-0871

Osaka University Hospital, Suita-shi

340-0041

Saiyu Soka Hospital, Soka-shi

693-8501

Shimane University Hospital, Izumo-shi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY